Phosphoinositide 3-kinase p110 alpha, p85 alpha, Recombinant, Bovine (PI3K)

\n\n\nPI3Ka plays a specific role in apoptosis in human colon cancer cells. Injection of neutralizing antibodies specific to PI3Ka into adenocarcinoma cells induced apoptosis, a response that was reverted by treating cells with caspase inhibitor. It was also shown that PI3Ka mediated\nphosphorylation of the p85a adapter reduces the lipid kinase activity of the heterodimer and this gives hints for PI3K-dependent signaling events not requiring production of 3

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

P4073-37H

Size

10ug

Form

Liquid. Supplied in 25mM Tris, pH 8.0, 50mM NaCl, 0.5mM MgCl2 and 50% glycerol.

Purity

(same/more than) 90% by SDS-PAGE

References

Foster et al. (2003) The phosphoinositide (PI) 3-kinase family. J. Cell Science 116:3037.\nYin et al. (1998) Involvement of p85 in p53-dependent apoptotic response to oxidative stress. Nature 391:707.\nShepherd et al. (1996) The role of phosphoinositide 3-kinase in insulin signalling. Journal of Molecular Endocrinolgy 17:175.\nSayama et al. (2002) Phosphatidylinositol 3-kinase is a key regulator of early phasedifferentiation in keratinocytes. J. Biol. Chem. 277:40390.\nCantrell, D.A. (2001) Phosphoinositide 3-kinase signalling pathways. J. Cell Sci. 114:1439.\nPirola et al. (2001) Activation Loop Sequences Confer Substrate Specificity to Phosphoinositide 3-Kinase a (PI3Ka). J. Biol. Chem. 276:21544.\nBenistant et al. (2000) A specific function for phosphatidylinositol 3- kinase alpha (p85alpha-p110alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in de novo DNA synthesis of human colon carcinoma cells. Oncogene 19:5083.\n